Guerard Frederic

SEC source: 0001825009-26-000003 · form4-10052026_091056.xml · derivative · entry 1

Guerard Frederic · CIK 0001825009 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2036-09-30

F1 · derivative.exercise_date: Beginning August 19, 2026, 1/12th of the shares subject to the option vest in equal monthly installments over a one year period, provided that the option will in any case be fully vested on the date of the 2027 annual meeting of stockholders of CalciMedica, Inc.

SEC source: 0001825009-26-000002 · form4-08212026_100850.xml · derivative · entry 1

Guerard Frederic · CIK 0001825009 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2036-08-18

F1 · derivative.exercise_date: 1/12th of the shares subject to the option vest in equal monthly installments over a one year period following the date of grant, provided that the option will in any case be fully vested on the date of the 2027 annual meeting of stockholders of CalciMedica, Inc.

SEC source: 0001825009-26-000001 · wk-form4_1781569078.xml · derivative · entry 1

Guerard Frederic · CIK 0001825009 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,100

Underlying: Common Stock · 22,100 shares

Expires 2036-06-15

F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be an Outside Director (as defined in the Issuer's Outside Director Compensation Policy) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier to occur of June 15, 2027 or the date of the next annual meeting of stockholders.

SEC source: 0001415889-25-018304 · form4-06262025_100609.xml · derivative · entry 4

Guerard Frederic · CIK 0001825009 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2035-06-23

F5 · derivative.exercise_date: 1/12th of the shares subject to the option vest in equal monthly installments over a one year period following June 24, 2025, provided that the shares will in any case be fully vested on the date of Company's 2026 annual meeting of stockholders

SEC source: 0001415889-25-018304 · form4-06262025_100609.xml · derivative · entry 3

Guerard Frederic · CIK 0001825009 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2035-04-22

F1 · date: The option grant was approved by the Board of Directors of CalciMedica, Inc. (the "Company") on April 23, 2025, subject to stockholder approval of an amendment of the Company's 2023 Equity Incentive Plan (the "Amended 2023 EIP") under which the option was granted. The Company's stockholders approved the Amended 2023 EIP on June 24, 2025.

F4 · derivative.exercise_date: 1/9th of the shares subject to the option vest in equal monthly installments over a one year period following April 1, 2025.

SEC source: 0001415889-25-018304 · form4-06262025_100609.xml · derivative · entry 2

Guerard Frederic · CIK 0001825009 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,000

Underlying: Common Stock · 5,000 shares

Expires 2035-04-22

F1 · date: The option grant was approved by the Board of Directors of CalciMedica, Inc. (the "Company") on April 23, 2025, subject to stockholder approval of an amendment of the Company's 2023 Equity Incentive Plan (the "Amended 2023 EIP") under which the option was granted. The Company's stockholders approved the Amended 2023 EIP on June 24, 2025.

F3 · derivative.exercise_date: Immediately exercisable.

SEC source: 0001415889-25-018304 · form4-06262025_100609.xml · derivative · entry 1

Guerard Frederic · CIK 0001825009 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2035-04-22

F1 · date: The option grant was approved by the Board of Directors of CalciMedica, Inc. (the "Company") on April 23, 2025, subject to stockholder approval of an amendment of the Company's 2023 Equity Incentive Plan (the "Amended 2023 EIP") under which the option was granted. The Company's stockholders approved the Amended 2023 EIP on June 24, 2025.

F2 · derivative.exercise_date: 1/12th of the shares subject to the option vest in equal monthly installments over a one year period following March 26, 2025.

SEC source: 0001815776-25-000046 · wk-form4_1749678377.xml · derivative · entry 1

Guerard Frederic · CIK 0001825009 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,500

Underlying: Common Stock · 13,500 shares

Expires 2035-06-10

F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be an Outside Director (as defined in the Issuer's Outside Director Compensation Policy) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on June 11, 2026.

SEC source: 0001415889-24-022509 · form4-08282024_110854.xml · derivative · entry 1

Guerard Frederic · CIK 0001825009 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2034-08-26

F1 · derivative.exercise_date: 1/12th of the shares subject to the option vest in equal monthly installments over a one year period following March 28, 2024.

SEC source: 0001415889-24-011354 · form4-04232024_010415.xml · derivative · entry 1

Guerard Frederic · CIK 0001825009 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2034-03-27

F1 · derivative.exercise_date: 1/12th of the shares subject to the option vest in equal monthly installments over a one year period following the date of grant.

SEC source: 0001815776-24-000027 · wk-form4_1711413647.xml · derivative · entry 3

Guerard Frederic · CIK 0001825009 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,000

Underlying: Common Stock · 27,000 shares

Expires 2034-03-20

F4 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2024 Equity Incentive Plan) through each applicable date, one thirty-sixth (1/36th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean March 21, 2024.

SEC source: 0001815776-24-000027 · wk-form4_1711413647.xml · derivative · entry 2

Guerard Frederic · CIK 0001825009 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,571

Underlying: Common Stock · 23,571 shares

Expires 2033-06-19

F1 · date: Stock option assumed in connection with the closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of November 14, 2023 (the "Merger Agreement"), by and among the Issuer, Generate Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the issuer, and LENZ Therapeutics Operations, Inc. (previously named Lenz Therapeutics, Inc.), a Delaware corporation ("LENZ OpCo"), in exchange of an outstanding option to purchase shares of LENZ OpCo, pursuant to the terms and conditions of the Merger Agreement.

F3 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the LENZ Therapeutics Operations, Inc. (previously named Lenz Therapeutics, Inc.) 2020 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean March 6, 2023.

SEC source: 0001815776-24-000027 · wk-form4_1711413647.xml · derivative · entry 1

Guerard Frederic · CIK 0001825009 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,897

Underlying: Common Stock · 30,897 shares

Expires 2031-09-16

F1 · date: Stock option assumed in connection with the closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of November 14, 2023 (the "Merger Agreement"), by and among the Issuer, Generate Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the issuer, and LENZ Therapeutics Operations, Inc. (previously named Lenz Therapeutics, Inc.), a Delaware corporation ("LENZ OpCo"), in exchange of an outstanding option to purchase shares of LENZ OpCo, pursuant to the terms and conditions of the Merger Agreement.

F2 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the LENZ Therapeutics Operations, Inc. (previously named Lenz Therapeutics, Inc.) 2020 Equity Incentive Plan) through each applicable date, one forty-eighth (1/48th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean September 17, 2021.

SEC source: 0001209191-23-021303 · doc4.xml · derivative · entry 3

Guerard Frederic · CIK 0001825009 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 83,705 shares

Expires not disclosed

F1 · derivative.exercise_price: Reflects a 14-to-1 reverse stock split effective March 17, 2023. Under the terms of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended (the "Merger Agreement"), by and among CalciMedica, Inc. ("Private CalciMedica"), the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), on March 20, 2023, Merger Sub merged with and into Private CalciMedica (the "Merger"), with Private CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common capital stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. In connection with the Merger, the vesting of Frederic Guerard's options and restricted stock units ("RSUs") were fully accelerated and the RSUs were settled on March 23, 2023.

F1 · price: Reflects a 14-to-1 reverse stock split effective March 17, 2023. Under the terms of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended (the "Merger Agreement"), by and among CalciMedica, Inc. ("Private CalciMedica"), the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), on March 20, 2023, Merger Sub merged with and into Private CalciMedica (the "Merger"), with Private CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common capital stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. In connection with the Merger, the vesting of Frederic Guerard's options and restricted stock units ("RSUs") were fully accelerated and the RSUs were settled on March 23, 2023.

F1 · derivative.exercise_date: Reflects a 14-to-1 reverse stock split effective March 17, 2023. Under the terms of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended (the "Merger Agreement"), by and among CalciMedica, Inc. ("Private CalciMedica"), the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), on March 20, 2023, Merger Sub merged with and into Private CalciMedica (the "Merger"), with Private CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common capital stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. In connection with the Merger, the vesting of Frederic Guerard's options and restricted stock units ("RSUs") were fully accelerated and the RSUs were settled on March 23, 2023.

F1 · derivative.expiration_date: Reflects a 14-to-1 reverse stock split effective March 17, 2023. Under the terms of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended (the "Merger Agreement"), by and among CalciMedica, Inc. ("Private CalciMedica"), the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), on March 20, 2023, Merger Sub merged with and into Private CalciMedica (the "Merger"), with Private CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common capital stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. In connection with the Merger, the vesting of Frederic Guerard's options and restricted stock units ("RSUs") were fully accelerated and the RSUs were settled on March 23, 2023.

SEC source: 0001209191-23-021303 · doc4.xml · nonDerivative · entry 2

Guerard Frederic · CIK 0001825009 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,727

F1 · shares: Reflects a 14-to-1 reverse stock split effective March 17, 2023. Under the terms of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended (the "Merger Agreement"), by and among CalciMedica, Inc. ("Private CalciMedica"), the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), on March 20, 2023, Merger Sub merged with and into Private CalciMedica (the "Merger"), with Private CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common capital stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. In connection with the Merger, the vesting of Frederic Guerard's options and restricted stock units ("RSUs") were fully accelerated and the RSUs were settled on March 23, 2023.

SEC source: 0001209191-23-021303 · doc4.xml · nonDerivative · entry 1

Guerard Frederic · CIK 0001825009 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 111,110

F1 · shares: Reflects a 14-to-1 reverse stock split effective March 17, 2023. Under the terms of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended (the "Merger Agreement"), by and among CalciMedica, Inc. ("Private CalciMedica"), the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), on March 20, 2023, Merger Sub merged with and into Private CalciMedica (the "Merger"), with Private CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common capital stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. In connection with the Merger, the vesting of Frederic Guerard's options and restricted stock units ("RSUs") were fully accelerated and the RSUs were settled on March 23, 2023.

F1 · price: Reflects a 14-to-1 reverse stock split effective March 17, 2023. Under the terms of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended (the "Merger Agreement"), by and among CalciMedica, Inc. ("Private CalciMedica"), the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), on March 20, 2023, Merger Sub merged with and into Private CalciMedica (the "Merger"), with Private CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common capital stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. In connection with the Merger, the vesting of Frederic Guerard's options and restricted stock units ("RSUs") were fully accelerated and the RSUs were settled on March 23, 2023.

SEC source: 0001209191-23-016513 · doc4.xml · derivative · entry 5

Guerard Frederic · CIK 0001825009 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 918,750

Underlying: Common Stock · 65,625 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

F5 · derivative.exercise_date: The RSUs shall vested as to 6.25% of the total shares on November 16, 2022, and 6.25% of the remaining shares shall vest quarterly thereafter such that the RSUs shall be fully vested on August 16, 2026, subject to the continued service of the Reporting Person to the Issuer through each vesting date.

F3 · derivative.expiration_date: The RSUs do not expire; they either vest or are canceled prior to vest date.

SEC source: 0001209191-23-016513 · doc4.xml · derivative · entry 4

Guerard Frederic · CIK 0001825009 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 221,746 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

F4 · derivative.exercise_date: The RSUs shall vested as to 100% of the total RSUs on February 28, 2023 and settled on March 3, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

F3 · derivative.expiration_date: The RSUs do not expire; they either vest or are canceled prior to vest date.

SEC source: 0001209191-23-016513 · doc4.xml · derivative · entry 3

Guerard Frederic · CIK 0001825009 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 253,125

Underlying: Common Stock · 28,125 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

F2 · derivative.exercise_date: The RSUs vested as to 1/4 of the total shares on May 19, 2022, and 1/16 of the remaining shares shall vest quarterly thereafter such that the RSUs shall be fully vested on May 19, 2025, subject to the continued service of the Reporting Person to the Issuer through each vesting date.

F3 · derivative.expiration_date: The RSUs do not expire; they either vest or are canceled prior to vest date.

SEC source: 0001209191-23-016513 · doc4.xml · nonDerivative · entry 2

Guerard Frederic · CIK 0001825009 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 383,682

SEC source: 0001209191-23-016513 · doc4.xml · nonDerivative · entry 1

Guerard Frederic · CIK 0001825009 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 473,026

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

SEC source: 0001209191-22-059205 · doc4.xml · derivative · entry 3

Guerard Frederic · CIK 0001825009 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 281,250

Underlying: Common Stock · 28,125 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

F2 · derivative.exercise_date: The RSUs vested as to 1/4 of the total shares on May 19, 2022, and 1/16 of the remaining shares shall vest quarterly thereafter such that the RSUs shall be fully vested on May 19, 2025, subject to the continued service of the Reporting Person to the Issuer through each vesting date.

F3 · derivative.expiration_date: The RSUs do not expire; they either vest or are canceled prior to vest date.

SEC source: 0001209191-22-059205 · doc4.xml · nonDerivative · entry 2

Guerard Frederic · CIK 0001825009 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 157,530

SEC source: 0001209191-22-059205 · doc4.xml · nonDerivative · entry 1

Guerard Frederic · CIK 0001825009 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 168,598

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

SEC source: 0001209191-22-058949 · doc4.xml · derivative · entry 3

Guerard Frederic · CIK 0001825009 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 984,375

Underlying: Common Stock · 65,625 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

F2 · derivative.exercise_date: The RSUs shall vested as to 6.25% of the total shares on November 16, 2022, and 6.25% of the remaining shares shall vest quarterly thereafter such that the RSUs shall be fully vested on August 16, 2026, subject to the continued service of the Reporting Person to the Issuer through each vesting date.

F3 · derivative.expiration_date: The RSUs do not expire; they either vest or are canceled prior to vest date.

SEC source: 0001209191-22-058949 · doc4.xml · nonDerivative · entry 2

Guerard Frederic · CIK 0001825009 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 140,473

SEC source: 0001209191-22-058949 · doc4.xml · nonDerivative · entry 1

Guerard Frederic · CIK 0001825009 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 166,297

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

SEC source: 0001209191-22-047722 · doc4.xml · derivative · entry 1

Guerard Frederic · CIK 0001825009 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,050,000

Underlying: Common Stock · 1,050,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

F2 · derivative.exercise_date: The RSUs shall vest as to 6.25% of the total shares on November 16, 2022, and 6.25% of the remaining shares shall vest quarterly thereafter such that the RSUs shall be fully vested on August 16, 2026, subject to the continued service of the Reporting Person to the Issuer through each vesting date.

F3 · derivative.expiration_date: The RSUs do not expire; they either vest or are canceled prior to vest date.

SEC source: 0001209191-22-047229 · doc4.xml · derivative · entry 3

Guerard Frederic · CIK 0001825009 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 309,375

Underlying: Common Stock · 28,125 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

F2 · derivative.exercise_date: The RSUs vested as to 1/4 of the total shares on May 19, 2022, and 1/16 of the remaining shares shall vest quarterly thereafter such that the RSUs shall be fully vested on May 19, 2025, subject to the continued service of the Reporting Person to the Issuer through each vesting date.

F3 · derivative.expiration_date: The RSUs do not expire; they either vest or are canceled prior to vest date.

SEC source: 0001209191-22-047229 · doc4.xml · nonDerivative · entry 2

Guerard Frederic · CIK 0001825009 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,672

SEC source: 0001209191-22-047229 · doc4.xml · nonDerivative · entry 1

Guerard Frederic · CIK 0001825009 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 107,268

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

SEC source: 0001209191-22-031348 · doc4.xml · derivative · entry 3

Guerard Frederic · CIK 0001825009 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 337,500

Underlying: Common Stock · 112,500 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

F2 · derivative.exercise_date: The RSUs vested as to 1/4 of the total shares on May 19, 2022, and 1/16 of the remaining shares shall vest quarterly thereafter such that the RSUs shall be fully vested on May 19, 2025, subject to the continued service of the Reporting Person to the Issuer through each vesting date.

F3 · derivative.expiration_date: The RSUs do not expire; they either vest or are canceled prior to vest date.

SEC source: 0001209191-22-031348 · doc4.xml · nonDerivative · entry 2

Guerard Frederic · CIK 0001825009 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 79,143

SEC source: 0001209191-22-031348 · doc4.xml · nonDerivative · entry 1

Guerard Frederic · CIK 0001825009 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 112,500

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

SEC source: 0001209191-22-015050 · doc4.xml · derivative · entry 2

Guerard Frederic · CIK 0001825009 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 221,746

Underlying: Common Stock · 221,746 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: The RSUs shall vests as to 100% of the total RSUs on February 28, 2023, subject to the Reporting Person's provision of service to the Issuer on the vesting date.

F3 · derivative.expiration_date: The RSUs shall vests as to 100% of the total RSUs on February 28, 2023, subject to the Reporting Person's provision of service to the Issuer on the vesting date.

SEC source: 0001209191-22-015050 · doc4.xml · derivative · entry 1

Guerard Frederic · CIK 0001825009 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 170,054

Underlying: Common Stock · 170,054 shares

Expires 2032-02-27

F1 · derivative.exercise_date: The stock option vests as to 100% of the total shares on February 28, 2023, subject to the Reporting Person's provision of service to the Issuer on the vesting date.

SEC source: 0001209191-21-034912 · doc4.xml · derivative · entry 2

Guerard Frederic · CIK 0001825009 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 450,000

Underlying: Common Stock · 450,000 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: The RSUs shall vest as to 1/4 of the total shares on May 19, 2022, and 1/16 of the remaining shares shall vest quarterly thereafter such that the RSUs shall be fully vested on May 19, 2025, subject to the continued service of the Reporting Person to the Issuer through each vesting date.

F4 · derivative.expiration_date: The RSUs do not expire; they either vest or are canceled prior to vest date.

SEC source: 0001209191-21-034912 · doc4.xml · derivative · entry 1

Guerard Frederic · CIK 0001825009 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 660,000

Underlying: Common Stock · 660,000 shares

Expires 2031-05-18

F1 · derivative.exercise_date: The stock option vests as to 1/4 of the total shares on May 19, 2022 and then 1/48 of the total shares monthly until the option is fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC source: 0001209191-20-062752 · doc4.xml · derivative · entry 1

Guerard Frederic · CIK 0001825009 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2030-12-07

F1 · derivative.exercise_date: The stock option vests as to 1/48 of the total shares on January 8, 2021 and each month thereafter until option is fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.